Legler Tobias J, Liu Zhong, Mavrou Ariadni, Finning Kirstin, Hromadnikova Ilona, Galbiati Silvia, Meaney Cathy, Hultén Maj A, Crea Francesco, Olsson Martin L, Maddocks Deborah G, Huang Dorothy, Fisher Sylvia Armstrong, Sprenger-Haussels Markus, Soussan Aicha Ait, van der Schoot C Ellen
Department of Transfusion Medicine, University of Göttingen, Göttingen, Germany.
Prenat Diagn. 2007 Sep;27(9):824-9. doi: 10.1002/pd.1783.
Cell free foetal DNA (cff DNA) extracted from maternal plasma is now recognized as a potential source for prenatal diagnosis but the methodology is currently not well standardized. To evaluate different manual and automated DNA extraction methods with a view to developing standards, an International Workshop was performed.
Three plasma pools from RhD-negative pregnant women, a DNA standard, real-time-PCR protocol, primers and probes for RHD were sent to 12 laboratories and also to one company (Qiagen, Hilden, Germany). In pre-tests, pool 3 showed a low cff DNA concentration, pool 1 showed a higher concentration and pool 2 an intermediate concentration.
The QIAamp DSP Virus Kit, the High Pure PCR Template Preparation Kit, an in-house protocol using the QIAamp DNA Blood Mini Kit, the CST genomic DNA purification kit, the Magna Pure LC, the MDx, the M48, the EZ1 and an in-house protocol using magnetic beads for manual and automated extraction were the methods that were able to reliably detect foetal RHD. The best results were obtained with the QIAamp DSP Virus Kit. The QIAamp DNA Blood Mini Kit showed very comparable results in laboratories that followed the manufacturer's protocol and started with > or = 500 microL plasma. One participant using the QIAamp DNA Blood Midi Kit failed to detect reliably RHD in pool 3.
This workshop initiated a standardization process for extraction of cff DNA in maternal plasma. The highest yield was obtained by the QIAamp DSP Virus Kit, a result that will be evaluated in more detail in future studies.
从母血血浆中提取的游离胎儿DNA(cff DNA)现已被公认为产前诊断的潜在来源,但目前该方法尚未得到很好的标准化。为了评估不同的手动和自动DNA提取方法以制定标准,举办了一次国际研讨会。
将来自RhD阴性孕妇的三份血浆池、一份DNA标准品、实时荧光定量PCR方案、用于RHD的引物和探针发送至12个实验室以及一家公司(德国希尔德的Qiagen公司)。在预试验中,第3号血浆池显示cff DNA浓度较低,第1号血浆池显示浓度较高,第2号血浆池显示浓度处于中间水平。
QIAamp DSP病毒试剂盒、高纯PCR模板制备试剂盒、使用QIAamp DNA血液微量提取试剂盒的内部方案、CST基因组DNA纯化试剂盒、Magna Pure LC、MDx、M48、EZ1以及使用磁珠进行手动和自动提取的内部方案均能够可靠地检测胎儿RHD。使用QIAamp DSP病毒试剂盒获得了最佳结果。在遵循制造商方案且起始血浆量≥500微升的实验室中QIAamp DNA血液微量提取试剂盒显示出非常相近的结果。一名使用QIAamp DNA血液中量提取试剂盒的参与者未能可靠检测出第3号血浆池中的RHD。
本次研讨会启动了母血血浆中cff DNA提取的标准化进程。QIAamp DSP病毒试剂盒的产量最高,这一结果将在未来研究中进行更详细的评估。